Prognostic Scores Validated for Additional Mutations in Secondary Myelofibrosis
Adding additional clinical and genetic information improved the performance of prognostic scores in secondary myelofibrosis, researchers in France report.
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 63 results for 'myelofibrosis'
Mutations & Proliferative Pathways Drive Myelofibrosis Evolution
Myeloproliferative neoplasms (MPN) are marked by the overproduction of myeloid cells, driven by JAK2, CALR, and MPL mutations. A recent study aimed to explain how these mutations result in various MPN phenotypes by sequencing...
Read More
Is Pelabresib + Ruxolitinib the Paradigm-Shifting Combo Therapy for Myelofibrosis?
Pelabresib plus ruxolitinib has shown efficacy in the treatment responses of patients with myelofibrosis.
Read More
Allogeneic HSCT for Myelofibrosis: What to Know as More Patients Receive Treatment
Authors of a recent review provide updates on stem cell transplants for myelofibrosis, with an emphasis on managing graft versus host disease and relapse.
Read More
Exploring the Role of Splenic Irradiation for Myelofibrosis Before HCT
The following is a summary of “Splenic irradiation for myelofibrosis prior to hematopoietic...
Read More
Pelabresib and Ruxolitinib Combination in Treatment-Naïve Myelofibrosis: MANIFEST Study Results
The following is a summary of “MANIFEST: Pelabresib in Combination With Ruxolitinib for...
Read MoreEarly intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral...
Read More
Momelotinib Yields Clinically Significant Improvement in Myelofibrosis
MONDAY, Feb. 6, 2023 (HealthDay News) — Treatment with momelotinib versus danazol yields...
Read More
How I Diagnose Primary Myelofibrosis.
Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN) with a...
Read MoreAdvertisement
Reduced intensity hematopoietic stem cell transplantation for myelofibrosis in accelerated-phase.
Accelerated-phase (AP) myelofibrosis, currently defined by circulating blasts 10-19%, usually confers very high risk for progression and poor outcome. The outcome of hematopoietic stem cell transplantation for AP myelofibrosis...
Read More
Febrile episode unmasking neuropsychiatric systemic lupus erythematosus with lytic lesions caused by secondary autoimmune myelofibrosis: Case report.
Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that...
Read More
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.
: Myelofibrosis (MF) is characterized by anemia, splenomegaly, constitutional symptoms and bone...
Read MoreRuxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor with scarce therapeutic possibilities.The authors performed a subanalysis of an observational, retrospective study (RUX-MF) that included...
Read More
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Ruxolitinib side effects include the most frequent hematological toxicity along with a more...
Read More
A multistate model of survival prediction and event monitoring in pre-fibrotic myelofibrosis
382 patients were taken as a sample with WHO-defined pre-PMF followed for a median of 6.9 years,...
Read MoreSafety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study.
The sonidegib and ruxolitinib combination was assessed in an open-label study in JAK inhibitor-naive patients with myelofibrosis (MF). The primary objective of phase 1b was to establish the maximum tolerated dose (MTD) and/or...
Read More
Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis.
COVID-19 carries a high risk of severe disease course, particularly in patients with...
Read More![[Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis].](https://cdn.physiciansweekly.com/wp-content/uploads/2020/11/iStock-1185598172.jpg)
[Angioimmunoblastic T-cell lymphoma complicated with various autoimmune abnormalities and myelofibrosis].
Angioimmunoblastic T-cell lymphoma (AITL) is frequently associated with immunological...
Read MorePatient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis.
This retrospective analysis evaluates morbidities, outcomes and associated risk factors in patients with myelofibrosis (MF) after ruxolitinib discontinuation, using Truven Health Analytics MarketScan® (TR), Optum™...
Read MoreHow Does Splenomagaly Impact Post-HCTs?
In a study published in the Journal of Clinical Oncology, researchers evaluated the impact of splenomegaly on post hematopoietic cell transplant (HCT) outcomes in patients with myelofibrosis using precise 3D volumetric...
Read More